Promising pipeline GLP agonists such as XW014, Survodutide, MK-6024, ECC5004, RGT001-075, Tirzepatide, CT 388, Pegylated exenatide, VK2735, MLX 7000 and others are under different phases of GLP agonist clinical trials
How to Maximize Your Results With Semaglutide Wegovy can be a helpful, life-changing tool for managing weight, but it is important to use it alongside a healthy lifestyle and nutrition plan
GLP-1 receptors are expressed in pancreatic islet cells, the gastrointestinal tract, vagal afferents, and brain regions involved in satiety and energy balance
Pemvidutide, developed by Altimmune, is a GLP-1/glucagon dual agonist that has completed Phase 2 trials for obesity (MOMENTUM, 15.6% weight loss at 48 weeks) and MASH (IMPACT, up to 59.1% MASH resolution)
Ro is also well-suited for people who value personalized, provider-led care
In comparison, semaglutide alone resulted in a 15.7% drop in weight, 71.8% of which was fat